✦ LIBER ✦

Three years' clinical experience with alefacept in 200 patients with chronic plaque psoriasis

Book ID: 116583953
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 48 KB
Volume: 58
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2007.10.553

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Alefacept revisited: Our 3-year clinical

Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis

✍ Amy Perlmutter; Jennifer Cather; Billy Franks; Eileen Jaracz; Alan Menter 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 252 KB

Alefacept Is Well Tolerated in Patients

Alefacept Is Well Tolerated in Patients with Chronic Plaque Psoriasis

✍ Alice B. Gottlieb 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 114 KB

Genetic polymorphisms associated with cl

Genetic polymorphisms associated with clinical improvement of chronic plaque psoriasis after treatment with alefacept

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Alefacept significantly reduces psoriasi

Alefacept significantly reduces psoriasis area and severity in people with chronic plaque psoriasis

✍ Dr B. Kirby 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 68 KB

The use of high-dose (30 mg/week) alefac

The use of high-dose (30 mg/week) alefacept in patients with chronic plaque psoriasis

📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Repeat courses of intravenous alefacept

Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy

✍ Nick J. Lowe; John Gonzalez; Jerry Bagel; Ivor Caro; Charles N. Ellis; Alan Ment 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB

## Abstract **Background** Psoriasis is a chronic, relapsing skin disease that may require multiple treatment courses. Alefacept targets the memory T cells implicated in psoriasis pathogenesis. This open‐label study evaluated the safety and tolerability, efficacy, and pharmacodynamics of repeat cou